Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CETIRIZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CETIRIZINE.
ACUVUE THERAVISION WITH KETOTIFEN vs Cetirizine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Cetirizine is a selective second-generation H1-receptor antagonist that inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
10 mg orally once daily; 5 mg orally once daily for mild symptoms
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Clinical Note
moderateCetirizine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate."
Clinical Note
moderateLevocetirizine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Cyclosporine
Terminal elimination half-life is approximately 8.3 hours in healthy adults; extended to 20 hours in elderly and patients with renal impairment
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal (60% unchanged in urine); minor biliary/fecal (10%)
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine
"The metabolism of Cyclosporine can be decreased when combined with Levocetirizine."